Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Relapsed and Refractory iMCD
NCT04743687Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2021
- Primary completion
- Jan 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in idiopathic multicentric Castleman disease (iMCD), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall Response Rate at 12 weeks. Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on NCT04743687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04743687.